Please login to the form below

Addressing the Gendered Health Data Gap

The Women’s Health Strategy for England presents an opportunity to ensure that gendered inequalities in health data are recognised and addressed. Caroline Cirado Perez’s ‘Invisible Women’ highlights how women are missing from data sets leading to health interventions and technologies designed for men as the default. For example, women are 50% more likely to be misdiagnosed following a heart attack because participation in clinical trials is generally skewed towards males. In her latest blog, Hanover Health’s Emma Gorton outlines why data should form a key part of the Women’s Health Strategy to help address inequalities in outcomes for women.

When thinking about personalised treatment today, we think of targeted cancer treatments, or gene therapies. Treatments that are designed for small subgroups of diseases or people and which are more effective because they are designed specifically for what they intend to do.

Whilst we have made huge strides in improving treatment for some of these conditions, it seems we are still missing a trick. Without the need for technological advances or medical innovation, we could better design our health systems and our treatments for 50% of the patient population. It seems an obvious place to start.

Everything created in our world has been thought through in terms of design: how high to put the shelving units in the supermarket, the temperature of your office and the safety specifications of your car. In making these decisions engineers and designers look at data to understand the optimal approach.

However, this only works when the data is representative of the people the design is aiming to serve, and all too often it isn’t. Women are often underrepresented or missing from these data sets resulting in a world that has been designed for men as default. This is also true of our healthcare systems; our clinical trials, our diagnostic approaches and our treatment options, all typically have men as the default.

Take heart attacks for example, the British Heart Foundation found women are 50% more likely to be misdiagnosed following a heart attack. One of the routine tests to diagnose a heart attack is the troponin test used to identify damage to heart cells. However, it was found that the expected ‘normal’ limits set were those that were normal for men as the default, leading to a higher incidence of women’s heart attacks going misdiagnosed. Women were missing from the data sets used to build the limits, and therefore the test becomes much less effective for women.

By using a more sensitive test and altering the expected limits to be appropriate for women, the number of women diagnosed with a heart attack doubled – women who otherwise would not have received a diagnosis, leading to delay in treatment and therefore worse outcomes overall.

As Caroline Cirado Perez points out in her book Invisible Women, this isn’t some malicious attempt to exclude half of the population from the world we design, it is just a consequence of non-representation. By not including women in the data sets used we continue to build systems with men as the default and this can have serious, and potentially deadly, consequences.

However, as the example above shows, the potential for positive change can be huge. By simply splitting data sets by sex, we can quickly and easily identify missing data, and find opportunities where addressing these could make a big impact to addressing gendered health inequalities. If this had been done in setting heart attack limits it would have become clear that there should be different levels for men and women.

The WHO’s Global Health Statistics were disaggregated by sex for the first time in 2019. So, whilst it’s a wonder that this wasn’t considered before 2019, it’s a step in the right direction. It’s a starting line.

In the UK, the Government are looking to address gendered health inequalities, bringing forward England’s first Women’s Health Strategy. Putting aside the fact that even the need for this clearly shows that women’s health isn’t covered by ‘health’ in itself, it is a great opportunity to address the gendered health data gap.

As we start to put more and more faith in data, the responsibility to make sure this data is representative of both women and men becomes stronger. A key part of the Women’s Health Strategy should be on ensuring women are included in the data sets used in health system design, clinical trials and disease management and also that the data is disaggregated to identify gendered differences.

Disaggregating these data has clear benefits for the female 50% of the population but it also has benefits for other groups; race, ethnicity and socioeconomic factors should all be taken into account too.

Not only will this ensure we are designing systems for all the people that will use them, but it will also mean we are able to see solutions we wouldn’t otherwise and uncover things that don’t intuitively feel true, or that we or others would never think to consider. For example, despite pregnant women being at increased risk from COVID-19, it took a campaigning group for them to gain access to the vaccine, a result that benefits the health system as a whole. At a time when the health system is recovering from the COVID-19 pandemic, finding smart, effective solutions to improving the health of the nation is paramount.

It is fascinating to think of the breakthroughs we may be able to take in medicine simply by challenging ourselves to ask the right questions and look at the right data. All of us are designers in our everyday lives, whether designing disease awareness campaigns or creating policy asks. We can all take a better look at the insights and data we use to inform our decisions and design, but we should also feel buoyed by the impact that we can have in making the world one that works for everyone.

9th June 2021


Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Riverside House
Southwark Bridge House
United Kingdom

Latest content on this profile

Femtech: Transforming the future of women's healthcare
Femtech is potentially the most important development in health care right now. Women's health has been under-researched and overlooked for successive generations - it's time that government and industry get ready to deliver.
Hanover Communications
VPAS: The importance of making the right arguments, even in challenging times
With key workers’ strikes, inflation, and immense pressure on public services, arguing for a more generous pricing settlement for the pharmaceuticals industry could not be tougher. Read our Health Director James Mole’s thoughts on the support needed to protect the UK life sciences’ ambitions, despite the challenging backdrop.
Hanover Communications
Putting prevention at the heart of the future of the NHS
Prioritising the prevention of cardiovascular disease (CVD) should be at the heart of plans to safeguard the long-term sustainability of the NHS. Unfortunately, action in this area has to date not matched ambition, putting thousands of patients’ lives – and the future of the health system – at risk.
Hanover Communications
Action on Anti-microbial resistance: Will the UK rise to the challenge
Timely and effective antimicrobials are the cornerstone of our healthcare systems, providing life-saving treatment and supporting vital services like routine operations, transplants and cancer treatment. We are three years into the UK Government’s 20-Year Vision for Antimicrobial Resistance (AMR), and the Department of Health and Social Care recently launched a consultation for the next iteration of the AMR National Action Plan (2024-2029). However, latest figures show that AMR is still on the rise. Is UK policy ambitious enough to drive innovation in AMR, and is the Government on track to contain, control and mitigate AMR by 2040?
Hanover Communications
Winter and workforce woes: challenges facing the new Secretary of State for Health and Social Care
For the third time this year, the NHS and social care has a new Secretary of State. The appointment must now signal stability following a period of political turbulence, as we head into what health leaders are describing as the toughest winter to date. Backlogs, delayed discharges, ambulance and A&E pressures, and crumbling NHS estates will remain top of Steve Barclay’s priority list in the coming weeks and months ahead. However, he will also need to address the longstanding workforce issues that hold back both the NHS and social care sector. Only dealing with these structural challenges will ensure the health and care system is operationally fit for winters to come.
Hanover Communications
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
The Truss Government has committ­ed to developing a new 10-year cancer plan. But set against the backdrop of the Secretary of States priorities, what real value can the sector expect a new cancer plan to deliver? What questions need addressing to drive impactful change for patients? Will there be funding available to support the transformation?  We will explore the state of play of cancer care in England and assess the main priorities, including how they align with wider NHS challenges. We will set out the difficult choices that a new plan must confront to enable prioritisation of this complex disease area and consider the balance between taking action to impact patients now versus initiatives to benefit patients of the future.
Hanover Communications